We are live on ! Find out more
O

OrbiMed Portfolio holdings

AUM $5.05B
1-Year Est. Return 125.28%
This Fund
S&P 500
This Quarter Est. Return
+13%
1 Year Est. Return
+125.28%
3 Year Est. Return
+334.72%
5 Year Est. Return
+344.07%
10 Year Est. Return
+2,748.76%
AUM
$10.5B
AUM Growth
+$923M
Cap. Flow
+$224M
Cap. Flow %
2.14%
Top 10 Hldgs %
34.54%
Holding
153
New
17
Increased
27
Reduced
30
Closed
10

Top Buys

Rank Stock Value
1
CMTA
Clementia Pharmaceuticals Inc.
CMTA
+$170M
2
AET
Aetna Inc
AET
+$79.5M
3
UHS icon
Universal Health Services
UHS
+$75.3M
4
KALA icon
KALA BIO
KALA
+$52.2M
5
IMMU
Immunomedics Inc
IMMU
+$50.5M

Top Sells

Rank Stock Value
1
HUM icon
Humana
HUM
+$185M
2
EW icon
Edwards Lifesciences
EW
+$51.3M
3
ICPT
Intercept Pharmaceuticals, Inc.
ICPT
+$50.6M
4
INSM icon
Insmed
INSM
+$48M
5
GKOS icon
Glaukos
GKOS
+$34.4M

Sector Composition

Rank Sector Weight
1 Healthcare 91.18%
2 Financials 2.54%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
OTIC
126
DELISTED
Otonomy, Inc.
OTIC
$2.09M 0.02%
644,074
-915,000
-59% -$12.3M
XENE icon
127
Xenon Pharmaceuticals
XENE
$6.17B
$1.87M 0.02%
634,812
– –
MCRB icon
128
CALL
Seres Therapeutics
MCRB
$45.9M
$1.2M 0.01%
+3,750
New +$1.02M
BLRX
129
BioLineRX
BLRX
$12.3M
$1.16M 0.01%
1,731
– –
AFMD
130
DELISTED
Affimed
AFMD
$735K 0.01%
32,665
-147,305
-82% -$3.19M
NVLN
131
DELISTED
Novelion Therapeutics Inc. Common Shares
NVLN
$703K 0.01%
100,000
– –
LUMO
132
CALL
DELISTED
Lumos Pharma, Inc. Common Stock
LUMO
$509K ﹤0.01%
+5,556
New +$426K
XTNT icon
133
Xtant Medical Holdings
XTNT
$59.1M
$343K ﹤0.01%
39,620
– –
ALIM
134
DELISTED
Alimera Sciences
ALIM
$338K ﹤0.01%
16,667
– –
ROKA
135
DELISTED
Sorrento Tech, Inc. Common Stock
ROKA
$147K ﹤0.01%
201,617
-691,853
-77% -$1.25M
XYLO
136
DELISTED
Xylo Technologies
XYLO
$134K ﹤0.01%
375
– –
ARAV
137
CALL
DELISTED
Aravive, Inc. Common Stock
ARAV
$123K ﹤0.01%
+8,333
New +$841K
AMRN
138
Amarin Corp
AMRN
$300M
– –
-10,243
Closed -$826K
AZN icon
139
PUT
AstraZeneca
AZN
$271B
– –
-125,000
Closed -$8.52M
CLLS
140
Cellectis
CLLS
$287M
– –
-66,799
Closed -$1.73M
HUM icon
141
Humana
HUM
$43.9B
– –
-770,900
Closed -$185M
JAZZ icon
142
CALL
Jazz Pharmaceuticals
JAZZ
$16.1B
– –
-100,000
Closed -$15.6M
NERV icon
143
Minerva Neurosciences
NERV
$195M
– –
-43,022
Closed -$3.05M
NVRO
144
CALL
DELISTED
NEVRO CORP.
NVRO
– –
-75,000
Closed -$5.58M
SIEN
145
DELISTED
Sientra, Inc.
SIEN
– –
-48,335
Closed -$4.7M
MNK
146
PUT
DELISTED
MALLINCKRODT PUBLIC LIMITED COMPANY
MNK
– –
-200,000
Closed -$8.96M
TSRO
147
DELISTED
TESARO, Inc.
TSRO
– –
-30,301
Closed -$4.24M
2 3 4 5
6

Similar funds

HSA
HBK Sorce Advisory Erie, Pennsylvania $5.05B AUM 16.64% 1-Year Est. Return
NL
NEPC LLC Boston, Massachusetts $5.02B AUM 7.87% 1-Year Est. Return
BPWM
Badgley Phelps Wealth Managers Seattle, Washington $5.02B AUM 21.87% 1-Year Est. Return
LFG
Lazard Frères Gestion Paris, France $5.07B AUM 20.66% 1-Year Est. Return
JIM
Jensen Investment Management Lake Oswego, Oregon $5.07B AUM 4.98% 1-Year Est. Return
CTC
Central Trust Company Jefferson City, Missouri $5.08B AUM 25.65% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return
SGM
Skye Global Management West Palm Beach, Florida $5B AUM 11.9% 1-Year Est. Return

OrbiMed's Q3 2017 Portfolio in Review

As of Q3 2017, OrbiMed held 153 positions worth $10.5B, up 9.7% from $9.54B the previous quarter. Its ten largest holdings account for 35% of the portfolio.

OrbiMed's Q3 2017 filing shows 17 new, 27 increased, 30 reduced and 10 closed positions. Its largest new stake was Clementia Pharmaceuticals Inc.: 10,425,225 shares worth $176M. The largest sale was Humana, an estimated $185M.

By sector, the portfolio is most concentrated in Healthcare at 91% of assets, down from 93% a quarter earlier, followed by Financials.

  • OrbiMed's largest Q3 2017 buy was Clementia Pharmaceuticals Inc.: 10,425,225 shares worth $176M.
  • OrbiMed added most to Aetna Inc in Q3 2017, an estimated $79.5M increase.
  • OrbiMed's biggest Q3 2017 reduction was Edwards Lifesciences, cutting an estimated $51.3M.
  • OrbiMed fully exited Humana in Q3 2017, selling an estimated $185M.
  • OrbiMed's ten largest holdings make up 35% of its $10.5B portfolio in Q3 2017.
  • OrbiMed opened 17 new positions and closed 10 in Q3 2017.
  • OrbiMed's portfolio value rose 9.7% quarter-over-quarter to $10.5B.

Based on OrbiMed's 13F filing for Q3 2017, filed 14 Nov 2017.